January 27, 2026
The ASO developed by this team activates a “cold shock” protein named RBM3 that protects brain cells—without needing to cool the body.
January 27, 2026
This project will study how epilepsy changes the way CCK interneurons work and whether fixing their activity can reduce seizures and improve memory, motivation, and behavior.
January 27, 2026
In this project, she and her team will study why these cells stay in a disease state in epilepsy and look for ways to help them return to normal.
January 27, 2026
The goal of this project is to develop a novel Antisense Oligonucleotide (ASO) strategy to treat DEE syndromes by changing how certain genes are processed within the cell.
January 27, 2026
Dr. Lisgaras and his team will test whether precise control of HFOs can provide powerful new therapeutic options. If successful, this work could pave the way for innovative treatments that improve seizure control and transform epilepsy care.
